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Using methanol extraction combined with HPLC and a new radioimmunoassay, the peptide head activator 
was detected in human plasma at a concentration of 20-100 fmoI/ml. Synthetic head activator incubated 
with plasma was degraded with a half-life of 7 min. Analysis of sites of enzymatic cleavage and inhibition 
by captopril showed a major involvement of angiotensin-converting enzyme in this process. Endogenous 
head activator, on the other hand, was not appreciably degraded upon incubation of plasma in vitro. These 
findings raise the possibility that the endogenous peptide could bind to a protective carrier molecule and 
reach potential target tissues via the blood circulation. 
Hydra head activator Radioimmunoassay Human plasma 
Angiotensin-converting enzyme 
HPLC Neuropeptide 
1. INTRODUCTION 
The hydra head activator (HA) is an undecapep- 
tide originally discovered in hydra where it exerts 
stimulatory effects on growth and differentiation 
processes involved in head formation [1,2]. Its 
sequence, Glp-Pro-Pro-Gly-Giy-Ser-Lys-V~-Ile- 
Leu-Phe, was determined from hydra and sea 
anemones [3] and subsequently from rich mam- 
malian sources such as human and bovine 
h~oth~amus as well as rat intestine [4]. Investiga- 
tions on the physiological role of this peptide in 
mammals indicate that, in addition to other func- 
tions, it could be involved in digestion control pro- 
cesses, since it was found to stimulate amylase 
secretion from rat pancreas in vitro [S]. From its 
prominent location in the upper part of the small 
intestine it could be released and reach the pan- 
creas via the blood circulation. Here, we took ad- 
vantage of a new sensitive radioimmunoassay 
(RIA) for the HA f6] to demonstrate that this pep- 
tide circulates in human plasma at a concentration 
of 20-100 fmollml. Synthetic peptide added to 
plasma was rapidly degraded. We describe here the 
predominant role of angiotensin-converting en- 
zyme (ACE, EC 3.14.15.1) in this process. The 
concentration of endogenous HA, however, re- 
mained constant upon incubation of plasma in 
vitro, thereby suggesting a mechanism for protec- 
tion of the peptide from proteolytic activity. These 
findings raise the possibility that the HA could ex- 
ert actions of physiological significance via the 
circulation. 
2. MATERIALS AND METHODS 
HA was obtained from Bachem, Switzerland. 
[3H]Pro2*3-HA (40-60 Ci/mmol) was prepared by 
catalytic tritiation of (3,4~ehy~o-Pro2,3)-HA as 
in [7]. [3H]Phe11-HA (30 Ci/mmol~ was obtained 
upon catalytic tritiation of (4’-I)Phe”-HA in the 
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laboratory of Dr J.-L. Morgat, Centre d’Etudes 
Nucleaires, Saclay, France. Affinity chroma- 
tography-purified rabbit lung ACE was a generous 
gift from Dr Peter Biinning, Freiburg. Captopril 
(SQ 14,225) was given by Dr Thomas Unger, 
Heidelberg, teprotide (SQ 20,881) was purchased 
from Bachem, soybean trypsin inhibitor from 
Sigma, Miinchen, and phenylmethylsulfonyl 
fluoride from Serva, Heidelberg. 
2.2. Extraction of HA from human plasma and 
radioimmunoassay 
For determination of the concentration of HA in 
plasma (see section 3.1), blood from fasting 
human volunteers was collected in EDTA 
(l-2 mg/ml). Blood collected in heparin 
(50 IE/ml) was used as a source of plasma for all 
other studies. The extraction procedure in [7] was 
applied without modification. Briefly, endogenous 
HA was extracted twice in 9-fold excess (v/v) of 
methanol and further purified by adsorption to C18 
Sep-pak cartridges (Waters) equilibrated with 
water. After washing with water and 20% 
methanol, HA was desorbed with 80% methanol. 
The HA content of the extracts was determined in 
a RIA employing 1251-labelled Tyr”-HA as a tracer 
[6] and the antiserum 12/4 showing N-terminal 
specificity [7]. 
2.3. Assay of HA-degrading activity 
All incubations were performed at 37°C. The 
reaction was initiated by addition of [3H]Phe11- 
HA at the indicated concentration and terminated 
by acidification to pH 2 with 0.5% trifluoroacetic 
acid (TFA). The C-terminal degradation fragments 
could be rapidly and conveniently separated from 
intact HA by applying 1 ml of the acidified mix- 
ture on a Cis Sep-pak cartridge equilibrated with 
water. The cartridge was then sequentially washed 
with 1 ml water and 6 ml of 30% methanol which 
eluted all the labeled C-terminal fragments of HA. 
These eluates were collected together in radio- 
activity vials, frozen to -8O”C, lyophilised and 
counted for radioactivity in a Kontron MR beta 
counter. Intact HA was eluted with 80% 
methanol. The cartridge could then be washed with 
10 ml methanol, regenerated with 10 ml water and 
reutilized up to 10 times. 
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2.4. HPLC separation and amino acid analysis of 
HA fragments 
Samples containing high concentration of pro- 
tein were applied on Sep-pak cartridges 
equilibrated with water and washed with 2 ml 
water. The peptides were eluted with 10 ml 
methanol and concentrated by rotatory evapora- 
tion. HPLC separation was performed using a Cs 
reverse phase column (LiChrosorb, 5 pm particle 
size) of 250 x 4 mm column size for work involv- 
ing synthetic peptide or 250 x 10 mm for analysis 
of endogenous HA. Elution was carried out with a 
40 min linear gradient from 0 to 40% acetonitrile 
in 0.1% TFA at a flow rate of 1 ml/min for the 
first column and 4 ml/min for the second one. For 
determination of radiolabeled fragments, l-ml 
fractions were collected and counted for radioac- 
tivity. Emerging peaks destined for amino acid 
determination were collected, dried and hydrol- 
ysed in 6 N HCl at 110°C for 24 h. Amino acid 
analysis was performed after dansylation by thin- 
layer chromatography [3] and quantitative confir- 
mation was obtained using a Biotronik analyser. 
3. RESULTS 
3.1. Concentration of HA in plasma 
The amount of immunoreactive HA was deter- 
mined after methanol extraction and purification 
on Sep-pak cartridges in a RIA using 1251-labelled 
Tyr”-HA as a tracer and antiserum 1214 which 
binds preferentially to the N-terminal portion of 
HA [7]. The concentration found for different in- 
dividuals was in the range 20-100 fmol/ml. 
Chromatography on reverse-phase HPLC yielded 
one major peak of immunoreactivity of retention 
time identical to that of tritiated synthetic HA 
(fig.1). The competition line of this material was 
parallel to that of HA (not shown) and this im- 
munoreactivity was therefore most probably due 
to HA itself. 
3.2. Degradation of HA in plasma 
The degradation of tritiated HA added to 
plasma was monophasic, showing a half-life of 
7 min (fig.2). Plasma was subjected to gel filtra- 
tion on a Sephacryl S-300 column (Pharmacia) 
equilibrated with 25 mM hydroxyethylpiperazine- 
sulfonic acid, 150 mM NaCl, pH 7.5 at 4°C. The 
HA-degrading activity was measured by hydrolysis 
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Fig.1. Reverse phase HPLC of human plasma 
immunoreactive HA (I-HA). Two-min fractions were 
collected, lyophilised and the content of I-HA was 
measured as described in section 2.2. The coiumn was 
calibrated with 13H]Phe”-HA in a separate run. 
of [3H]Phe’1-HA and eluted as one major peak of 
K,, = 0.25 (fig.3). The active fractions were pooled 
and referred to as the ‘Kav = 0.25 peak’. A second, 
minor peak of activity of M, 30000 was sometimes 
detected and then represented less than 15% of the 
degrading activity recovered from the column. 
This component was not further characterized in 
this study. The effect of a number of inhibitors on 
the degradation of HA by the K,, = 0.25 peak is 
presented in table 1. The inhibitors of serine-de- 
pendent proteases, phenylmethylsulfonyl fluoride 
and soybean trypsin inhibitor showed little or no 
effect. The ACE inhibitors captopril and teprotide 
exerted powerful inhibition at low concentrations. 
The chelating agent EDTA and the sulfhydryl 
compound dithiothreitol were also potent in- 
hibitors. Captopril at a concentration of 10e6 M 
could completely inhibit the degradation of 
tritiated HA by plasma over a period of more than 
15 min (fig.2). Purified rabbit lung ACE applied 
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Fig.2. Degradation of HA in plasma. Plasma was 
preincubated 20 min at 37°C without (0) or with 
lop6 M captopril (a) and aliquots were removed at 
various times after addition of 0.9 nM [3H]Phe”-HA. 
Intact HA was separated from degradation fragments as 
described in section 2.3. 
on the Sephacryl S-300 column eluted at the same 
position as the HA-degrading peak (fig.3). These 
data strongly suggested identity of the Kav = 0.25 
peak with ACE and to assess this possibility fur- 
ther, we compared the sites of cleavage of HA by 
these two enzyme activities. 
3.3. Identification of degradation products 
The use of HA tracers tritiated at either end of 
the peptide proved ideal to identify the peptide 
fragments produced by the enzyme activity of the 
plasma. [3H]Pro2*3-HA was used to localize pep- 
tide fragments containing the N-terminal sequence 
of HA and [3H]Phe1*-HA to trace the C-terminal 
peptides. The degradation fragments produced by 
plasma and by the Kav = 0.25 peak were compared 
to those produced with purified ACE after separa- 
tion on reverse phase HPLC with a gradient of 
acetonitrile in 0.1% TFA. These results are shown 
in fig.4. The degradation pattern of [3H]Pro2*3-HA 
was similar in all three cases. It showed two peaks 
309 
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Fig.3. Sephacryl S-300 separation of HA-degrading 
activity of human plasma. Plasma (4.5 ml) was applied 
on the column and the elution of proteins was monitored 
by absorbance at 254 nm (- - -). The column was 
equilibrated with 25 mM hydroxyethylpiperazinesul- 
fonic acid, 150 mM NaCl (pH 7.5) at 4°C: 5-ml frac- 
tions were collected and l-ml samples were assayed for 
HA-degrading activity with 0.6 nM [3H]Phe11-HA as 
described in section 2.3. In a separate run, purified 
rabbit lung ACE was applied on the column and its 
elution was monitored by change in absorbance at 
328 nm during incubation with the substrate furanacryl- 
oyl-Phe-Gly-Gly [9], and by hydroIysis of 
of radioactivity with retention times of 13 and 
25 min in addition to intact HA which eluted at 
36 min. Following incubation with plasma, the 
Kay = 0.25 peak and purified ACE, [SH]Phe”-HA 
degradation yielded one common peak of retention 
time 28 min apart from intact HA. In addition, a 
peak of radioactivity eluting at 13 min was pro- 
duced upon incubation with plasma and the &” = 
0.25 peak, but not after incubation with purified 
ACE. To determine the amino acid composition of 
these fragments, unlabeled HA (50 nmob’ml) was 
incubated with purified ACE and the degradation 
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Table I 
Effect of inhibitors on the degradation of HA by the 
I& = 0.25 peaka 
Inhibitor Concen- % In- 
tration hibition 
Phenylmethylsulfonyl- 
fluoride 1O-3 M 5.2 
Soybean trypsin 
inhibitor 0.1 mg/ml l-2 
Captopril 1O-7 M 92.5 
1O-8 M 62. I
Teprotideb 1O-5 M 99.2 
1O-6 M 97.8 
EDTA 1o-3 M 99.6 
Dithiothreitol 1o-3 M 91.1 
a Fractions 44-5 1 from Sephacryl S-300 separation were 
pooled and 1 ml preincubated 20 min at 37*C with the 
various inhibitors at the indicated concentrations. The 
reaction was initiated by adding 0.6 nM [3H]Phe”-HA 
and terminated after 3 h by acidification with 0.5% 
TFA. The extent of degradation was measured as 
described in section 2.3 
b Teprotide: Glp-Trp-Pro-Arg-Pro-Gln-Be-Pro-Pro 
peptides were separated by HPLC and monitored 
by absorbance at 210 nm. Fig.5 shows the chroma- 
tographic profile generated after 2 h incubation. 
The retention times and amino acid analysis of 
these peaks are summarized in table 2. The results 
show cleavage of HA at the Gig-Se?, Lys7-Val* 
and Ilee-Leui’ peptide bonds. The reaction yielded 
the dipeptides Leu-Phe and Val-Ile. This is consis- 
tent with the known dipeptidyl carboxypeptidase 
activity of ACE. The dipeptide Ser-Lys was not 
detected but was probably also produced since the 
fragments Gtp-Pro-Pro-Gly-Gly-Ser-Lys and Glp- 
Pro-Pro-Gly-Gly were produced. We suspect hat 
this dipeptide eluted in the flow-through of the col- 
umn because of its hydrophilic properties. The 
time course study of generation of these degrada- 
tion products (fig.6) shows a disappearance of HA 
proportional to the appearance of Leu-Phe in the 
medium. The Glp-Pro-Pro-Gly-Gly-Ser-Lys-VaI- 
Ile fragment first accumulated but its concentra- 
tion began to drop after 2 h as Val-Ile was formed. 
This demons~ates the sequential removal of Leu- 
Phe and Val-Ile from HA. The fragment Glp-Pro- 
Pro-Gly-Gly-Ser-Lys which should be produced 
upon cleavage of Val-Ile was not detected in our 
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Fig.4. Reverse phase HPLC of degradation fragments 
produced by incubation of [3H]Pro2*3-HA (0) and 
[3H]Phe”-HA (0) with plasma (A), the Kay = 0.25 peak 
(B) and purified ACE (C). The tritiated peptides were 
incubated 30 min with 100~1 plasma, 3 h with 1 ml 
K,, = 0.25 peak and 90 min with 0.7 mg/ml purified 
ACE. HPLC separation was performed as in section 2.4. 
K#‘O.2! 
pea 
2000 - 
g 1000 - 
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chromatograms. It was possibly very rapidly de- 
graded to Glp-Pro-Pro-Gly-Gly and Ser-Lys which 
accumulated in the medium and not lost on HPLC 
separation because quantitation of the peptide 
fragments did not show any loss of N-terminal 
peptide. Comparison of these results with those 
obtained by incubating radioactive HA with 
plasma and with the K,, = 0.25 peak (fig.4) shows 
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Fig.5. Reverse phase HPLC of HA degradation by 
purified ACE. HA (50 nmol/ml) was incubated 2 h at 
37°C with 0.7 mg/ml ACE in 50 mM hydroxyethyl- 
piperazinesulfonic acid, 300 mM NaCl (PH 7.5) and 
5 nmol were submitted to HPLC as in section 2.4 (upper 
curve). Control incubations were performed without 
substrate (lower curve). 
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Table 2 
HPLC separation of peptides derived from degradation of HA by angiotensin-converting enzyme 
Peak Retention time Peptidea 
(min) 
1984 
13 GIp-Pro-Pro-Gly-Gly 
18 Val-Be 
25 Glp-Pro-Pro-Gly-Gly-Ser-Lys-Val-Be 
28 Leu-Phe 
36 Glp-Pro-Pro-Gly-Gly-Ser-Lys-VaI-Be-Leu-Phe 
a Determined by amino acid analysis as described in section 2.4 
that the proline-labeled peaks of retention times 13 
and 25 min correspond to peaks a and c and that 
the phenylalanine-labeled peak of retention time 
28 min is Leu-Phe (peak d). With the exception of 
fragment Val-Ile which is not labeled and therefore 
could not be detected by the tracer method, the 
fragments produced by the enzyme activity of the 
plasma and the K,, = 0.25 peak correspond to 
those produced by ACE and are the result of a 
dipeptidyl carboxypeptidase activity. The only dif- 
ference, namely the phenylalanine-labeled peak 
which elutes at 13 min, was identified as tritiated 
Phe on the following basis: HPLC of progressively 
Tme (hi 
Fig.& Time course of degradation of HA by ACE. HA 
(50 nmob’ml) was incubated with purified ACE 
(0.7 mg/ml) in 50 mM hydroxyethylpiperazinesulfonic 
acid, 300 mM NaCl (PH 7.5) and aliquots were 
submitted to HPLC at different times. The amount of 
peptide in each peak was determined by quantitative 
amino acid analysis as described in section 2.4. The 
peptides are Iabeled a-e and their amino acid 
To determine whether plasma endogenous HA is 
degraded with the same kinetics as exogenous yn- 
thetic peptide, fresh plasma was incubated at 37°C 
and aliquots were removed at different times for 
determination of HA content by RIA after 
methanol extraction and HPLC purification. The 
concentration of endogenous HA did not decrease 
with time, suggesting that the peptide occurs in 
plasma in a form which is protected from enzyme 
degradation. 
4. DISCUSSION 
composition is given in table 2. Here, we have found that the peptide HA occurs 
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shorter C-sequences of HA starting from Ser-Lys- 
Val-Ile-Leu-Phe to Phe showed that only free Phe 
eluted at this position. It was most probably pro- 
duced by cleavage of the fragment Leu-Phe rather 
than by a carboxypeptidase activity on HA itself. 
This interpretation is strengthened by the observa- 
tion that the appearance of radioactivity in the Phe 
peak was proportional to the disappearance of 
radioactivity in the Leu-Phe peak at time points 
where no more labeled HA was present in the 
medium (not shown). Moreover, the Phe peak was 
not produced in the presence of concentrations of 
captopril which inhibit ACE but not most of the 
other peptidases. It has been indeed demonstrated 
that dipeptide-degrading activity often copurifies 
with ACE isolated from plasma even after several 
isolation steps of the converting enzyme [8]. The 
affinity chromatography-purified rabbit lung ACE 
used in this study was devoid of such a con- 
taminating dipeptid~e activity. 
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in human plasma at a concentration of 
20- 100 fmol/ml. This value is comparable to most 
of the other peptide hormones whose unstimulated 
plasma concentrations are usually within the range 
5-150 fmol/ml. Synthetic tritiated HA was 
degraded by a plasma enzyme which was identified 
as ACE on the following basis: (i) purified ACE 
and the HA-degrading activity eluted at the same 
position on Sephacryl S-300 gel filtration; (ii) the 
HA-degrading activity was inhibited by the ACE 
inhibitors captopril and teprotide at concentra- 
tions allowing for extensive inhibition of ACE 
while leaving most of other protease activities 
unaffected [lo], and by EDTA which is also a po- 
tent inhibitor of the Zn’+-dependent ACE [ll]; 
(iii) the degradation patterns of both ACE and the 
plasma HA-degrading enzyme were similar, 
liberating dipeptidyl residues from the C-terminus 
of HA. 
ACE is known to occur in human plasma 
[ 11,121. However, plasma is not the main source of 
ACE activity of the organism, In fact, most of the 
enzyme is bound to the luminal surface of en- 
dothelial cells with particularly high concentra- 
tions in the lungs. The half-life of angiotensin I in 
plasma is of the order of minutes while in vivo, it 
is transformed to angiotensin II in the 3-5 s re- 
quired for the blood to pass through the 
pulmonary circulation [ 131. At physiological con- 
centrations, bradykinin is also almost completely 
inactivated on passage through the lung circulation 
[ 141. It is therefore to be expected that the half-life 
of 7 min estimated for HA in human plasma 
would be considerably shorter upon injection of 
the peptide in the blood circulation. Indeed, we 
have observed that the half-life of HA injected in 
the venous circulation of anesthetized rats, which 
includes a clearance part in addition to enzymatic 
degradation, is less than 30 s while the half-life 
measured in plasma in vitro was similar to that in 
human plasma (unpublished). However, the en- 
dogenous circulating HA was found to be very 
stable against proteolytic degradation. This could 
be due to adsorption of HA to a larger molecule. 
This possibility is substantiated by preliminary ex- 
periments which indicate that an important pro- 
portion of the plasma peptide is adsorbed to a pro- 
tein fraction which elutes on molecular sieve col- 
umns in the high molecular mass range. This 
association could protect the HA from degrada- 
tion. The peptide can be desorbed from this frac- 
tion by methanol extraction, a procedure normally 
used for HA isolation. The behavior of this ex- 
tracted molecule both on HPLC and in the RIA in- 
dicates identity with synthetic HA. 
More investigations will be required to 
characterize this carrier molecule and the type of 
binding which renders the peptide resistant o pro- 
teolytic degradation. 
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